Suzhou Acumen Biomedical Secures $13.8 Million in Series A+ Funding Round
China’s Suzhou Acumen Biomedical Technology Co., Ltd. has reportedly raised close to RMB 100 million...
MicroPort MedBot’s SkyWalker Robot Approved for Orthopedic Surgery by NMPA
Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) has announced that it has received marketing...
Zhejiang Medicine Gets NMPA Approval for NCB003 Clinical Study for Advanced Solid Tumors
Zhejiang Medicine Co., Ltd (SHA: 600216), a China-based pharmaceutical company, has announced that it has...
Zelgen Biopharmaceuticals’ rhTSH Achieves Primary Endpoint in Phase III Study
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266), a China-based pharmaceutical company, has announced that its...
China’s CDE Proposes Removal of Ambroxol Inhalation Solution and Four Other Drugs
The Center for Drug Evaluation has issued a notification concerning the Chemical Generic Drug Reference...
CSBIO’s Albenatide Shows Positive Results in Two Phase III Diabetes Trials
Hebei Changshan Biochemical Pharmaceutical Co., Ltd (CSBIO; SHE: 300255) has announced encouraging results from two...
Sandoz Receives Positive CHMP Review for Trastuzumab Biosimilar in HER2-Positive Cancers
Sandoz (SWX: SDZ), the generic and biosimilar drug maker set to separate from Novartis (NYSE:...
NMPA Drafts Quality Management Norms for Online Medical Device Sales
The National Medical Products Administration (NMPA) has issued the “Medical Device Online Sales Quality Management...
NMPA Seeks Comments on Medical Device Classification Draft Proposal
The National Medical Products Administration (NMPA) has issued a notification focusing on the definition and...
Gilead’s Kite CAR-T Therapy Yescarta Achieves 71% CMR in Phase II Trial for R/R LBCL Patients
Gilead’s (NASDAQ: GILD) subsidiary Kite has announced early results from a Phase II trial of...
Pharmanovia Bolsters Neurology Portfolio with Acquisition of Sanofi’s CNS Products
UK-based healthcare company Pharmanovia has announced the expansion of its neurology portfolio through the strategic...
Tonghua Dongbao Pharmaceuticals Partners with King-Friend Biochemical on Insulin Development
China-based Tonghua Dongbao Pharmaceuticals (SHA: 600867) has entered into a partnership with fellow Chinese firm...
EMA’s CHMP Backs Enhertu for Advanced NSCLC with HER2 Mutations
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...
BMS Expands Partnership with Samsung Biologics for Oncology Drug Manufacturing
Global pharmaceutical company Bristol-Myers Squibb (BMS; NYSE: BMY) has announced an expansion of its existing...
EMA’s CHMP Recommends Approval of Keytruda as Adjuvant NSCLC Treatment
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...
Novartis’s Kisqali Reduces Cancer Recurrence Risk in HR+/HER2- Early Breast Cancer: Phase III Results
Swiss pharmaceutical giant Novartis (NYSE: NVS) has published results from a Phase III study of...
CanSino Biologics Reports H1 2023 Revenues Down 96.7% YOY, COVID-19 Demand Decreases
China-based CanSino Biologics (SHA: 688185, HKG: 6185) has released its financial report for the first...
GemPharmatech Partners with Daxiang Biotech to Advance Preclinical Evaluation Models
Nanjing-based GemPharmatech Co., Ltd, a center for laboratory animal seed resources and a specialist in...
Akeso Biopharma’s AK132 Receives Green Light for Clinical Trial in Advanced Solid Tumors
Akeso Biopharma’s (HKG: 9926) AK132, a bispecific antibody (BsAb) targeting Claudin18.2 and CD47, has received...
AcornMed Receives FDA Breakthrough Device Designation for Urothelial Carcinoma Liquid Biopsy
Beijing-based tumor precision medicine specialist, AcornMed, has been granted Breakthrough Device Designation (BDD) by the...